Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution

Rahul Narayan Maddi; Vijay Gandhi Linga; Kalpathi Krishnamani Iyer; Joseph Stalin Chowdary; Sadashivudu Gundeti; Raghunadharao Digumarti; Tara Roshini Paul

doi:10.4103/0971-5851.171550

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2015; 36(04): 255-260
DOI: 10.4103/0971-5851.171550

ORIGINAL ARTICLE

Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution

Authors

Rahul Narayan Maddi

Department of Medical Oncology, Chalmeda Anand Rao Institute of Medical Sciences, Karimnagar, India
Vijay Gandhi Linga

Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India
Kalpathi Krishnamani Iyer

Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India
Joseph Stalin Chowdary

Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India
Sadashivudu Gundeti

Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India
Raghunadharao Digumarti

Director and Department of Medical Oncology, Tata Memorial Center, Vishakapatnam, Andhra Pradesh, India
Tara Roshini Paul

Department of Pathology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India

Abstract

PDF Download

Abstract

Treatment and outcome of Hodgkin lymphoma (HL) are the true success story of modern medicine. The data from the developing countries on long-term outcome of patients with HL is sparse. Aims: Primary objective is to assess the progression-free survival (PFS). Secondary objective are overall survival (OS) and toxicities. Settings and Design: This is a retrospective analysis from the case records from a single institution. Materials and Methods: Institutional Ethical Committee approval was obtained. Between January 1991 and December 2010, 301 patients (age ≥18 years) underwent treatment at our institution. Statistical Analysis: Kaplan-Meyer curves were used to calculate the PFS and OS. Results: The median age at presentation was 36 years, range from 19 to 75 years. The male to female ratio was 2.9:1. Seventy-five percent of patients had B symptoms. Majority presented in advanced stage (Stage III and IV) disease (64.7%). Mixed cellularity (74.4%) was the most common histology, followed by nodular sclerosis (13.9%). The most common chemotherapy regimen used was ABVD (61%). Conclusions: Median follow-up of the cohort was 18.5 months (range 2-225). PFS and OS rate at 5 years is 66.3% and 79.7% respectively.

Keywords

Chemotherapy and toxicities - Hodgkin lymphoma - survival

PDF (664 kb)

References

References
1 Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:1096-103.
2 Cerci JJ, Linardi CC, Pracchia LF, Junior JS, Trindade E, Delbeke D, et al. 2-[18F]-fluoro-2-desoxy-D-glucose positron emission tomography initial staging impacts on survival in Hodgkin lymphoma. World J Radiol 2013;5:484-90.
3 Diehl V, Thomas RK, Re D. Part II: Hodgkin′s lymphoma - Diagnosis and treatment. Lancet Oncol 2004;5:19-26.
4 Armitage JO. Early-stage Hodgkin′s lymphoma. N Engl J Med 2010;363:653-62.
5 Pulte D, Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, et al. Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21 st century. Br J Haematol 2014;164:851-7.
6 Shenoy P, Maggioncalda A, Malik N, Flowers CR. Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States. Adv Hematol 2011;2011:725219.
7 Bessell EM, Bouliotis G, Armstrong S, Baddeley J, Haynes AP, O′Connor S, et al. Long-term survival after treatment for Hodgkin′s disease (1973-2002): Improved survival with successive 10-year cohorts. Br J Cancer 2012;107:531-6.
8 Ganesan P, Kumar L, Raina V, Sharma A, Bakhshi S, Sreenivas V, et al. Hodgkin′s lymphoma - long-term outcome: An experience from a tertiary care cancer center in North India. Ann Hematol 2011;90:1153-60.
9 Ramadas K, Sankaranarayanan R, Nair MK, Nair B, Padmanabhan TK. Adult Hodgkin′s disease in Kerala. Cancer 1994;73:2213-7.
10 Dinshaw KA, Advani SH, Gopal R, Nair CN, Talvalkar GV, Gangadharan P, et al. Management of Hodgkin′s disease in western India. Cancer 1984;54:1276-82.
11 Shanta V, Sastri DV, Sagar TG, Sasikala K, Krishnamurthi S. A review of Hodgkin′s disease at the Cancer Institute, Madras. Clin Oncol 1982;8:5-15.
12 Dinshaw K, Pande S, Advani S, Ramakrishnan G, Nair C, Talvalkar G, et al. Pediatric Hodgkin′s disease in India. J Clin Oncol 1985;3:1605-12.
13 Chandi L, Kumar L, Kochupillai V, Dawar R, Singh R. Hodgkin′s disease: A retrospective analysis of 15 years experience at a large referral centre. Natl Med J India 1998;11:212-7.
14 Arya LS, Dinand V, Thavaraj V, Bakhshi S, Dawar R, Rath GK, et al. Hodgkin′s disease in Indian children: Outcome with chemotherapy alone. Pediatr Blood Cancer 2006;46:26-34.
15 Raina V, Sharma A, Mohanti BK, Kumar R, Dawar R, Rath GK. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin′s disease. Natl Med J India 2003;16:199-203.
16 Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, et al. Consolidation radiation after complete remission in Hodgkin′s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 2004;22:62-8.
17 Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin′s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
18 Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
19 Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
20 Gerhartz HH, Beykirch M, Hiller E, Wilmanns W. Chemotherapy dose and survival in advanced Hodgkin′s disease. Acta Haematol 1993;89:137-40.